Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk myelodysplastic syndrome
Phase 2
Completed
- Conditions
- low-risk myelodysplastic syndrome
- Registration Number
- JPRN-UMIN000005662
- Lead Sponsor
- Department of Hematology, Kinki University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with simultaneous multiple cancers. 2. Patients with history of hyper- sensitivity to mannitol 3. Patients with poorly-controlled infection requiring intensive care with antibiotics and antifungals. 4. Patients with poorly-controlled diabetes. 5. Patients with severe psychiatric disorder. 6. Pregnant or lactating females. 7. Patients with positive serology for HBs antigen, HCV antibody or HIV antibody. 8. Patients who is deemed as ineligible for this study by investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method